Compare ARKO & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARKO | FDMT |
|---|---|---|
| Founded | 1970 | 2013 |
| Country | United States | United States |
| Employees | 9748 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.8M | 515.6M |
| IPO Year | N/A | 2019 |
| Metric | ARKO | FDMT |
|---|---|---|
| Price | $5.96 | $9.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.50 | ★ $31.71 |
| AVG Volume (30 Days) | ★ 1.1M | 783.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $12.86 | N/A |
| Revenue Next Year | $1.49 | $70.28 |
| P/E Ratio | $56.88 | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $3.71 | $2.89 |
| 52 Week High | $6.71 | $12.34 |
| Indicator | ARKO | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 51.48 |
| Support Level | $5.80 | $8.41 |
| Resistance Level | $6.65 | $9.78 |
| Average True Range (ATR) | 0.24 | 0.64 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 97.01 | 46.71 |
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. It derives the majority of its revenue from retail and wholesale distribution of fuel.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).